A Randomized, Double-blind, Placebo-controlled, Single-dosing, Dose-escalating Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin SAL200 After Continuous Intravenous Infusion in Healthy Male Volunteers

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Single-dosing, Dose-escalating Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin SAL200 After Continuous Intravenous Infusion in Healthy Male Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs SAL 200 (Primary)
  • Indications Methicillin-resistant Staphylococcus aureus infections
  • Focus Adverse reactions
  • Sponsors iNtRON Biotechnology
  • Most Recent Events

    • 27 Mar 2017 Results published in the Antimicrobial Agents and Chemotherapy
    • 18 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Aug 2014 The final dosage has been tested, according to an iNtRON Biotechnology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top